Video by Eric Valor – ALS The Awful Truth. Research for ALS Treatment: SciOpen Research Group
In the next two hours, someone will be diagnosed with ALS. At any given moment 20,000 people across the country are affected by the disease. ALS is a neurodegenerative disease that attacks cells located in the brain and spinal cord, diminishing the ability to initiate and control muscle movement. Simple everyday activities become a challenge. Getting dressed in the morning or even lifting a pen to write turn into impossible tasks. Eventually, patients lose the ability to speak, move, and even breathe. Ultimately, the muscle deterioration leads to death. Heavy-heartedly the truth is most people with ALS die from respiratory failure, usually within 3 to 5 years of onset of symptoms. About 50% of patients live 2 years after diagnosis, only 20% live 5 years or more, and even less survive more than 10 years…While ALS is devastating, it doesn’t have to be incurable.
The FDA has approved Radicava™ (Edaravone), the first new treatment specifically for ALS. The drug’s list price is $1K per infusion, $11K per dosage cycle, which amounts to $146K per year.
Proper funding can allow for the research necessary to have a real impact.
LIFENET Technologies is partnering with the fight and will donate 10% of any purchase directly to help fund further research and development. ALS is not an incurable disease. It is an underfunded one. Get plugged into a LIFENET now and help the fight against this horrible disease at the links below…
Donations large or small help and can also be made directly on Eric N. Valor’s nonprofit research for treatment website SciOpen. Frequently asked questions about SciOpen and tax information can be found here. Like SciOpen on Facebook here or keep up with Eric on Facebook here and on YouTube here.